The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01E | Protein kinase inhibitors | |
| 4 | L01EA | BCR-ABL tyrosine kinase inhibitors | |
| 5 | L01EA01 | Imatinib |
| Active Ingredient | Description | |
|---|---|---|
| Imatinib |
Imatinib is a protein-tyrosine kinase inhibitor which potently inhibits the Bcr-Abl tyrosine kinase at the in vitro, cellular and in vivo levels. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| GILVEC Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| GLEEVEC Film coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
